Medifast (NYSE:MED) Releases FY 2026 Earnings Guidance

Key Points

• FY 2026 guidance: Medifast issued EPS guidance of -2.75 to -1.55 (vs. consensus -1.98) and revenue guidance of $270M–$300M (vs. consensus $275.3M), and updated Q2 2026 EPS guidance to -1.00 to -0.50.
• Shares fell about 3% to $10.58 after the update; the company did, however, beat recent quarterly expectations with EPS of ($0.19) vs. ($0.55) estimated and revenue of $76.04M vs. $69.20M expected.
• Analysts’ consensus rating is “Reduce” with an average target of $12, while CEO Daniel Chard bought 17,678 shares at $10.11 and institutional ownership stands around 95.5%.

Medifast (NYSE:MED - Get Free Report) issued an update on its FY 2026 earnings guidance on Monday morning. The company provided EPS guidance of -2.750--1.550 for the period, compared to the consensus EPS estimate of -1.980. The company issued revenue guidance of $270.0 million-$300.0 million, compared to the consensus revenue estimate of $275.3 million. Medifast also updated its Q2 2026 guidance to -1.000--0.500 EPS.

Medifast Trading Down 3.0%

Shares of NYSE:MED traded down $0.33 on Monday, reaching $10.58. 150,459 shares of the company traded hands, compared to its average volume of 241,666. The business's 50-day simple moving average is $10.41 and its 200 day simple moving average is $11.10. Medifast has a 52 week low of $9.22 and a 52 week high of $15.46. The stock has a market capitalization of $116.76 million, a P/E ratio of -6.19 and a beta of 0.55.

Medifast (NYSE:MED - Get Free Report) last released its quarterly earnings results on Monday, May 4th. The specialty retailer reported ($0.19) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.55) by $0.36. Medifast had a negative net margin of 4.84% and a negative return on equity of 4.27%. The company had revenue of $76.04 million during the quarter, compared to the consensus estimate of $69.20 million. Medifast has set its FY 2026 guidance at -2.750--1.550 EPS and its Q2 2026 guidance at -1.000--0.500 EPS. Sell-side analysts expect that Medifast will post -2 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on MED shares. Stephens decreased their price objective on shares of Medifast from $15.00 to $12.00 and set an "equal weight" rating for the company in a report on Thursday, February 19th. Weiss Ratings reissued a "sell (d)" rating on shares of Medifast in a research report on Thursday, January 22nd. Finally, Wall Street Zen upgraded shares of Medifast from a "sell" rating to a "hold" rating in a research note on Saturday, March 21st. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of "Reduce" and an average target price of $12.00.

Insider Buying and Selling at Medifast

In other news, CEO Daniel R. Chard acquired 17,678 shares of the business's stock in a transaction dated Friday, March 20th. The stock was purchased at an average price of $10.11 per share, for a total transaction of $178,724.58. Following the completion of the transaction, the chief executive officer directly owned 17,678 shares in the company, valued at approximately $178,724.58. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 3.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Medifast

A number of institutional investors and hedge funds have recently modified their holdings of the business. Lido Advisors LLC bought a new stake in shares of Medifast during the third quarter valued at approximately $4,521,000. Steamboat Capital Partners LLC bought a new position in Medifast in the fourth quarter worth approximately $2,952,000. Charles Schwab Investment Management Inc. increased its holdings in Medifast by 30.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 776,829 shares of the specialty retailer's stock worth $8,297,000 after purchasing an additional 181,618 shares during the period. Bank of America Corp DE increased its holdings in Medifast by 37.4% during the 2nd quarter. Bank of America Corp DE now owns 396,369 shares of the specialty retailer's stock worth $5,569,000 after purchasing an additional 107,854 shares during the period. Finally, Victory Capital Management Inc. bought a new stake in Medifast during the 3rd quarter valued at $867,000. 95.51% of the stock is owned by institutional investors.

Medifast Company Profile

Medifast, Inc NYSE: MED is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client's weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.